| Literature DB >> 31193831 |
Chunli Liu1,2, Chunlong Yuan3, Hosahalli S Ramaswamy4, Yamei Ren1, Xiaolin Ren5.
Abstract
The antioxidant activities in vitro and hepatoprotective effects against carbon tetrachloride (CCl4) induced acute liver injury in vivo of myristic acid acylated derivative of phloridzin (PZM) were investigated. The PZM was obtained by enzymatic acylation of myristic acid and phloridzin (PZ). The antioxidant capability of PZM in vitro was evaluated by the ferric reducing antioxidant power assay (FRAP), 2,2'-Azinobis- 3-ethylbenzthiazoline-6-sulphonate (ABTS+·) and 2,2-diphenyl-1-picrylhydrazyl (DPPH·) radical scavenging assay. Mice were intragastrically treated with control or PZM (20, 40, and 80 mg/kg) for 5 days and intra-peritoneal injection with CCl4. The enzymatic acylated synthesis of myristic acid and phloridzin was region-selective taken place on 6″-OH of phloridzin glycoside moiety and achieved 93% yield. PZM had a significantly higher total antioxidant ability, same scavenging ABTS+· ability and weaker scavenging DPPH· ability when compared to the parent PZ. The of aminotransferase serum activity and malondialdehyde hepatic activity were elevated (P < 0.015) after treatment with CCl4, while the related liver enzymatic activities and glutathione concentration were lower. These changes were enhanced by PZM. Further studies showed that PZM reduced the interleukin-6 expression and stimulated liver regeneration caused by CCl4. PZM attained good antioxidant capacity in vitro and had excellent hepatoprotective effects in vivo and better bioactivity compared to the parent phloridzin. The significance of hepatoprotective effect of phloridzin derivative against CCl4-induced hepatotoxicity in mice is an important and new finding.Entities:
Keywords: Food safety; Natural product chemistry; Organic chemistry; Pharmaceutical chemistry
Year: 2019 PMID: 31193831 PMCID: PMC6543077 DOI: 10.1016/j.heliyon.2019.e01761
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Fig. 1The structure of phloridzin (PZ).
Fig. 2Numbering of Phloridzin-6″-O-myristate.
Antioxidant capacity measured by FRAP, ABTS·+ and DPPH· radical assays for phloridzin (PZ) and myristic acid ester of phloridzin (PZM).
| Compound | FRAP (μmol AE L−1) | ABTS (μmol AE L−1) | DPPH (μmol AE L−1) |
|---|---|---|---|
| Phloridzin | 77.9 ± 5.17 | 1794 ± 20.7 | 3.99 ± 0.3 |
| PZM | 95.9 ± 3.77* | 1792 ± 85.1 | 1.76 ± 0.003** |
Results were expressed as Means ± SD, *P˂0.05, **P˂0.01.
Antioxidant activity unit: μmol ascorbic acid equivalents/L of 1 mM of solution; PZM: Phloridzin myristate.
Fig. 3Effects of PZM on the activities of ALT (A) and AST (B) in serum against CCl4-induced hepatoxicity in mice. Group I: normal control; group II: PZM control; group III: model; group IV: Silymarin-treated; group V: PZ-treated; group VI: PZM-treated (20 mg/kg); group VII: PZM-treated (40 mg/kg), group VIII: PZM-treated (80 mg/kg). Values are expressed as mean ± SD.∗P < 0.05, ∗∗P < 0.01 compared to normal group. +P < 0.05, ++P < 0.01 compared to model group.
Fig. 4Effects of PZM on the levels of CAT (A), SOD (B), GSH-Px (C), MDA (D) and GSH (E) against CCl4-induced hepatoxicity in mice. Group I: normal control; group II: PZM control; group III: model; group IV: Silymarin-treated; group V: PZ-treated; group VI: PZM-treated (20 mg/kg); group VII: PZM-treated (40 mg/kg), group VIII: PZM-treated (80 mg/kg). values are expressed as mean ± SD.∗P < 0.05, ∗∗P < 0.01 compared to normal group. +P < 0.05, ++P < 0.01 compared to model group.